Revvity Introduces New Workflow To Accelerate Newborn Sequencing Research
WALTHAM, MASS.--(BUSINESS WIRE)--
Revvity, Inc. today announced the introduction of a flexible end-to-end workflow solution for newborn research, enabling users to utilize different instruments, reagents and databases based on a lab’s needs.
“This new workflow from Revvity seeks to elevate the customer experience by leveraging a rich variant database for newborn sequencing research and providing critical components necessary to be able to go from sample to result,” said Madhuri Hegde, PhD, FACMG, SVP and chief scientific officer, Revvity. “We are accelerating the democratization of genomic sequencing by addressing the typical challenges faced by labs.”
The research-use only (RUO) offering from Revvity culminates in analysis and report, covering essential steps in the sequencing process. The solution enables identification of variants in more than 350 genes, complemented by a large database of carefully pre-curated variants. The offering includes dried blood spot collection and processing devices, Chemagic™ kits and instruments for nucleic acid extraction, liquid handlers and reagents for library preparation, VICTOR2™ D Instrument for sample quality control, and software capabilities. The workflow is compatible with the Element AVITI™ system and other leading NGS platforms.
For labs interested in outsourcing the workflow, Revvity’s Clinical Genomic Services provides solutions from delivery of a sample collection kit to final report, or the flexibility to access sequence data or report only to augment the customer’s in-house capabilities.
For research use only. Not for use in diagnostic procedures.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315457826/en/
Copyright Business Wire 2024